News Menopause

Health & Her ranked number one for menopause by ORCHA

By Published On: April 17, 2023
Health & Her ranked number one for menopause by ORCHA

The tracking app Health & Her has been ranked number one for menopause by the Organisation for the Review of Care and Health Apps (ORCHA).

The app, designed to help women build positive habits and monitor their symptoms, offers advice, personalised insights and tools, including pelvic floor training, meditation and CBT.

In its latest Orcha review, it scored 86 per cent, making it the highest ever ORCHA-rated menopause app available to women in the UK seeking support as they experience perimenopause and menopause.

Research suggests symptom monitoring and appraisal methods are effective for reducing menopausal symptoms, and improving health awareness, shared decision-making, patient-doctor communication, and treatment goal setting.

Kate Bache, co-founder and CEO of Health & Her, says she is thrilled with the recognition from this respected organisation.

“We are delighted to be recognised as the number one rated app for menopause. Unlike many other apps available for female health, we are also proud that our app is completely free to download and use.

“We are continually looking to improve the support for women going through hormonal change and we have worked hard to enhance the functionality in response to customer feedback.

“To receive this rating means that all our hard work is paying off and we are doing the right thing for women.”

ORCHA is Europe’s largest independent researcher of digital healthcare apps. It works closely with the NHS in establishing criteria for trustworthy apps.

The fact that 75 per cent of health apps fail to pass the ORCHA review process makes the rating of the Health & Her app even more impressive, says Bache.

“Having this level of ORCHA rating means that GPs and those working in the NHS can feel confident to recommend our app as a practical support tool for women.”

Thousands of women in Scotland to be invited for cervical screening after they were incorrectly excluded
Women-led cancer support platform secures £3.4m investment